High-impact,
de-risked drug development
Galenicap transforms known drug molecules into clinically differentiated therapies with clear paths to early clinical validation and exit. By building on validated biology and existing compounds, we reduce development risk while accelerating timelines and preserving significant upside potential, while addressing meaningful unmet medical needs.
A repeatable platform for clinical and commercial value
Our platform systematically identifies, designs, and advances new therapeutic products with improved clinical profiles, defensible intellectual property, and strong commercial positioning. By focusing on areas where current treatments fall short, we aim to deliver tangible benefits for patients while creating multiple high-value assets and repeatable opportunities for value creation.
De-risked by design
Our programs start from known drugs with validated mechanism, reducing biological uncertainty and increasing the probability of success while maintaining a strong clinical foundation.
Differentiated products
Each asset is engineered to deliver meaningful improvements for patients, whether through better efficacy, improved safety, or more practical treatment options.
Built for exit
We develop assets to early clinical proof, typically Phase I or II, where strong market demand enables licensing or strategic transactions that bring these therapies closer to patients.
A growing portfolio of
high-impact programs
With eight active programs across central nervous system disorders, oncology, and infectious disease, Galenicap operates a diversified portfolio designed to generate both near-term value inflection points and long-term upside, while targeting areas of significant unmet medical need.
Latest news & events
Galenicap enters into drug repurposing collaboration with US university
​
June 17, 2025
Galenicap BV and Neurevo GmbH created Glicothera BV, a specialty pharma focused on a new neuroprotective agent for stroke
May 13, 2025
Galenicap co-founded Aclathera BV, a specialty pharma dedciated to the development of new cancer treatments
March 28, 2025